Should I buy or sell Scilex stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCLX shares. View SCLX analyst ratings or view top-rated stocks .

What is Scilex's stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for Scilex's stock. Their SCLX share price targets range from $4.00 to $12.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 583.8% from the stock's current price. View analysts price targets for SCLX or view top-rated stocks among Wall Street analysts .

How have SCLX shares performed in 2024?

Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 42.6% and is now trading at $1.17. View the best growth stocks for 2024 here .

When is Scilex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our SCLX earnings forecast .

How were Scilex's earnings last quarter?

Scilex Holding (NASDAQ:SCLX) released its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.04. The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $11.43 million.

What ETFs hold Scilex's stock?

ETFs with the largest weight of Scilex (NASDAQ:SCLX) stock in their portfolio include Morningstar US Small Growth (MSGR) , Amplify Treatments, Testing and Advancements ETF (GERM) , Global X Genomics & Biotechnology ETF (GNOM) and Invesco PureBeta MSCI USA Small Cap ETF (PBSM) . Nationwide Russell 2000 Risk-Managed Income ETF (NTKI) .

Who are Scilex's major shareholders?

Scilex's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.02%) and Collective Family Office LLC (0.01%).

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SCLX

Scilex (SCLX) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free SCLX Stock Alerts

$1.17

+0.01 (+0.86%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.16
▼
$1.22
50-Day Range: $1.16
▼
$2.42
52-Week Range: $0.90
▼
$14.65

Volume: 732,328 shs
Average Volume: 800,122 shs
Market Capitalization: $194.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Scilex alerts:

Scilex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 583.8% Upside
$8.00 Price Target
Short Interest: Bearish
6.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

742nd out of 913 stocks

Biological Products, Except Diagnostic Industry

120th out of 148 stocks

3.5

Analyst's Opinion

Consensus Rating
Scilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Scilex has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.40% of the float of Scilex has been sold short.
Short Interest Ratio / Days to Cover
Scilex has a short interest ratio ("days to cover") of 7.2.
Change versus previous month
Short interest in Scilex has recently decreased by 3.09%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Scilex does not currently pay a dividend.
Dividend Growth
Scilex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SCLX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 4 news articles for Scilex this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
58 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scilex insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.73% of the stock of Scilex is held by insiders.
Percentage Held by Institutions
69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Scilex are expected to grow in the coming year, from ($0.51) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Scilex is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Scilex is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Scilex Stock (NASDAQ:SCLX)

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

SCLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SCLX Stock News Headlines

April 16, 2024 | msn.com

Scilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattack

April 16, 2024 | globenewswire.com

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 14, 2024 | americanbankingnews.com

Scilex (SCLX) & Its Peers Financial Comparison

April 13, 2024 | americanbankingnews.com

Financial Comparison: Scilex (SCLX) & Its Rivals

April 10, 2024 | americanbankingnews.com

Scilex (SCLX) & Its Rivals Head to Head Review

April 9, 2024 | globenewswire.com

Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool

April 9, 2024 | americanbankingnews.com

Reviewing Scilex (NASDAQ:SCLX) & TRACON Pharmaceuticals (NASDAQ:TCON)

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 27, 2024 | globenewswire.com

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

March 21, 2024 | globenewswire.com

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

March 20, 2024 | globenewswire.com

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

March 20, 2024 | globenewswire.com

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®

March 19, 2024 | msn.com

Scilex Holding repays the remaining balance of convertible debentures

March 19, 2024 | globenewswire.com

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

March 18, 2024 | globenewswire.com

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

March 16, 2024 | finance.yahoo.com

SCLX Apr 2024 2.000 put

March 16, 2024 | finance.yahoo.com

SCLX Apr 2024 1.000 put

March 15, 2024 | globenewswire.com

Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

March 15, 2024 | markets.businessinsider.com

Scilex Pharma Enters Definitive Mutual Release And Settlement Agreement With Virpax

March 15, 2024 | finance.yahoo.com

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement

March 15, 2024 | globenewswire.com

Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement

March 14, 2024 | finance.yahoo.com

Scilex Holding Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 12, 2024 | finance.yahoo.com

SCLX Grows Revenue and Boosts Marketing

March 9, 2024 | finance.yahoo.com

Scilex Holding Company (NASDAQ:SCLX) most popular amongst private companies who own 57% of the shares, institutions hold 25%

March 6, 2024 | msn.com

SCLX Continues to Make Strides

March 5, 2024 | globenewswire.com

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

See More Headlines

Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SCLX
CUSIP: N/A
CIK: 1820190
Web: www.scilexholding.com
Phone: 650-516-4310
Fax: N/A
Employees: 105
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $12.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +583.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,330,000.00
Net Margins: -244.60%
Pretax Margin: -244.57%
Return on Equity: N/A
Return on Assets: -112.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.19
Quick Ratio: 0.17

Sales & Book Value

Annual Sales: $46.74 million
Price / Sales: 4.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.10) per share
Price / Book: -1.06

Miscellaneous

Outstanding Shares: 166,190,000
Free Float: 151,682,000
Market Cap: $194.44 million
Optionable: Optionable
Beta: 0.68

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Henry H. Ji Ph.D. (Age 60)
Executive Chairman
Comp: $885.43k
Mr. Stephen Ma (Age 51)
Senior VP, CFO & Corporate Secretary
Comp: $708.78k
Mr. Jaisim Shah (Age 64)
President, CEO & Director
Comp: $785.73k
Dr. Suketu D. Desai Ph.D. (Age 58)
CTO & Senior VP
Ms. Gigi DeGuzman
Executive Director of Administrative Operations & Head of Human Resources
Mr. Steven F. Lincoln J.D.
General Counsel & Chief Compliance Officer
Mr. Sumant Rajendran
Executive Director of Marketing
Mike Ciaffi
National Sales Director
Mr. Suresh K. Khemani (Age 64)
Senior VP & Chief Commercial Officer
Comp: $456.82k
Dr. Dmitri V. Lissin M.D. (Age 64)
Senior VP & Chief Medical Officer
Comp: $528.83k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SCLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Scilex stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCLX shares.
View SCLX analyst ratings or view top-rated stocks.
What is Scilex's stock price target for 2024?: 2 Wall Street analysts have issued 1 year price targets for Scilex's stock. Their SCLX share price targets range from $4.00 to $12.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 583.8% from the stock's current price.
View analysts price targets for SCLX or view top-rated stocks among Wall Street analysts.
How have SCLX shares performed in 2024?: Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 42.6% and is now trading at $1.17.
View the best growth stocks for 2024 here.
When is Scilex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our SCLX earnings forecast.

How were Scilex's earnings last quarter?: Scilex Holding (NASDAQ:SCLX) released its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.04. The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $11.43 million.
What ETFs hold Scilex's stock?: ETFs with the largest weight of Scilex (NASDAQ:SCLX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM) and Invesco PureBeta MSCI USA Small Cap ETF (PBSM).Nationwide Russell 2000 Risk-Managed Income ETF (NTKI).
Who are Scilex's major shareholders?: Scilex's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.02%) and Collective Family Office LLC (0.01%).
How do I buy shares of Scilex?: Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCLX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial